Blincyto (blinatumomab)

pCPA File Number: 23102

Negotiation Status:

Active Negotiation

Indication(s):

For the treatment of adult and pediatric patients with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy in the frontline setting.

Sponsor/Manufacturer:

Amgen Canada Inc.

CDA-AMC Project Number:

PC0365-000

pCPA Engagement Letter Issued:

2025-05-30

Negotiation Process Concluded:

Not Applicable